+ 1.47
+ 0.93%

Mydecine Snags License To Produce, Sell and Export Natural Psilocybin For Research

August 19, 2020 2:13 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Mydecine Innovations Group (CSE:MYCO) (OTC:MYCOF) announced Wednesday that it has begun to exercise its GMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin.

The psilocybin is naturally derived from whole-mushroom extraction.

The company claims to be the first organization to achieve this goal, since previous similar licenses only exist for synthetically-produced psilocybin. Extracting natural psilocybin from mushrooms could potentially be more cost-effective and more easily scalable to large-scale production.

“The ability to legally supply naturally-sourced psilocybin through our spore-to-sale process represents a major advancement for therapeutic medicine research,” said Mydecine co-founder and COO Damon Michaels. “Not only are these unique psychedelic compounds safe, but there is also a growing body of evidence to support its use as an effective treatment for afflictions, such as depression, anxiety, and PTSD.”

According to Josh Bartch, CEO and Director of Mydecine, the company will leverage its ability to produce purified pharmaceutical-grade psilocybin extracts and export its finished byproducts to its various research partners throughout the world, such as the Imperial College of London and Johns Hopkins University.  

“Psychedelic research is currently constrained by very high costs and inefficiently produced synthetic psilocybin,” Bartch told Benzinga. 

“Our ability to produce naturally-sourced medicine, paired with new-age technology, will help advance the medical community’s understanding of mental health and psychedelics,” he concluded.

Photo by Zhen Hu on Unsplash

Related Articles

Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space

Cybin Raises CA$45 Million and Heads Towards NEO Exchange read more

4 Lessons The Emerging Psychedelics Industry Can Learn from The Cannabis Boom

By Evan Nison, NisonCo PR. read more

3 Key Leadership Traits For Disruptive Psychedelic Drug Development

This article was originally published on Microdose Psychedelic Insights, and appears here with permission. read more

You Are Not Alone: Psychedelic Therapy And Mental Health Awareness

This article was originally published on Microdose Psychedelic Insights, and appears here with permission. “The humanity we all share is more important than the mental illness we may not.”  Elyn R. Saks read more

'Psyched': Study Finds MDMA More Cost-Effective Than Traditional PTSD Treatments, Pharmather Goes Public

MDMA-assisted psychotherapy would result significantly more cost-effective than current available treatment options for post-traumatic stress disorder, according to a study distributed by the Multidisciplinary Association for Psychedelic Studies.  read more